Compare Biogen Inc (BIIB) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs M&T Bank Corporation — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while M&T Bank Corporation trades at $245.32 (market cap $35.42B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays a 2.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MTB | |
|---|---|---|
Market Cap | $28.34B | $35.42B |
Sector | Health | Financials |
52-Week High | $216.63 | $242.55 |
52-Week Low | $122.68 | $178.63 |
Enterprise Value | $30.62B | — |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
M&T Bank Corporation (MTB) trades at $242.55, up 0.09% today, with a bullish technical signal supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.18 exceeding expectations of $4.02. Revenue grew to $9.63B in 2025, with a net income margin of 29.59%. Recent news highlights Q2 2026 results announcement on July 15, 2026, with expectations of higher net interest income and loan growth.
Outlook remains positive due to strong profitability and dividend stability, but risks include elevated costs and net cash flow volatility. Analyst consensus is mixed with 29% buy ratings, though the price target of $242.72 suggests limited upside from current levels. Investors should weigh solid fundamentals against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
